NewAmsterdam Pharma, a late-stage biopharmaceutical company focused on developing oral non-statin treatments for cardiovascular disease patients with high LDL cholesterol, announced its participation in two major investor conferences in June 2026. CEO Dr. Michael Davidson and EVP Matthew Philippe will hold fireside chats at the Jefferies Global Healthcare Conference in New York on June 3 and the Goldman Sachs Global Healthcare Conference in Miami on June 9. These presentations will be webcast live and archived on the company's website. This participation highlights NewAmsterdam's ongoing efforts to engage investors ahead of potential regulatory decisions and product launches expected in the second half of 2026.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
